Navigation Links
The National Park Foundation and Olympus Announce Winner of the First-Ever 'Your Parks' Video Challenge
Date:9/30/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Inc. (Nasdaq: ATSI ), manufacturer and marketer ... announced it has received CE Mark approval to ... the European Union, indicating it is compliant with ... The Enable valve is the first ... that is implanted using a sutureless technique. ...
(Date:12/7/2009)... EUCODIS Bioscience, a company,developing, customizing, manufacturing, and ... that it has appointed Mr Thomas Fischer,currently ... Going forward, EUCODIS Bioscience,sole focus will be ... the Company,s experience in commercial enzyme development ... recombination". , In ...
(Date:12/7/2009)... Dec. 7 CeNeRx BioPharma, Inc., a clinical ... central nervous system, today announced that a newly published ... novel compound TriRima (TM) reversibly inhibits MAO-A (monoamine ... a key role in the regulation of mood. ... class of selective and reversible inhibitors of MAO-A known ...
(Date:12/7/2009)... CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... a global biopharmaceutical company focused on endocrine therapy ... its European efficacy trial Z-036 in benign prostatic ... did not reach its primary endpoint. There were ... 3 groups (including placebo) showing an improvement in ...
Breaking Biology Technology:ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
... ... - Operating margin of 9.9% for the quarter,- Record backlog of over $2 ... ... today announced its financial results for the,fourth quarter and Fiscal Year ended June 30, 2008., For ...
... Partners announced today that,it has updated coverage and has ... INO ). "The proposed merger of Inovio and ... and deliver,therapeutic agents and positions Inovio/VGX, based on further ... other gene therapy,companies," said Ross Silver, Director of Research ...
... N.J., Aug. 6 Millennium,Biotechnologies, Inc., a wholly ... Board: MBTG) today named Mark C.,Mirken its new ... of,Directors., Mirken has been President and Chief ... in September of 2007. Mirken will replace Jerry,Swon ...
Other Biology Technology:PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target 2Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc. 2Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc. 3
(Date:12/7/2009)... Therapeutics, Inc., reversed the growth of lung tumors in ... The study reveals that a tiny bit of RNA ... treatment, and provides hope for future patients battling one ... "This is the first time anybody has shown a ... Frank Slack, Ph.D., co-senior author of the paper, researcher ...
(Date:12/7/2009)... 2009 (BRONX, NY) Matthew Levy, Ph.D., ... of Medicine of Yeshiva University, has been awarded ... (SU2C) for his high-risk/high-reward cancer research. Dr. Levy,s ... target only cancer cells, thus eliminating or significantly ... therapies. Dr. Levy is one of 13 young ...
(Date:12/6/2009)... York, N.Y./Los Angeles, Calif.: Stand Up To Cancer ... to support high-risk/high-reward cancer research conducted by 13 young ... a total of up to $750,000 as part of ... generation of cancer research leaders. , "We asked our ... comfort zones and strive to make big differences with ...
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6eCardio Included on Inc Magazines 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 55980 1eCardio Included on Inc Magazines 28th Annual List of Americas Fastest Growing Private Companies the Inc 500 55980 2Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 1Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 2Repligen to Present at the Rodman 26 Renshaw 11th Annual Healthcare Conference Wednesday September 9th 2 3A25 p m EDT 13791 3Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 1Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 2Jiangbo Pharmaceuticals to Present at Rodman 26 Renshaw Annual Global Investment Conference 13788 3
... in Quartier Concordia along Ste. Catherine street or De ... see a demonstration of innovative Canadian technology conceived at ... of one facade of an institutional building - the ... world-first demonstration of this type of combined solar heat ...
... Congress of the International Osteoporosis Foundation and the European ... Osteoarthritis, to be held in Florence, Italy from May ... opportunity for clinicians and researchers from around the world ... field of osteoporosis and osteoarthritis. The,congress will offer an ...
... being forced to say no to a child crying for ... imagine it; that was normal life at her family,s dinner ... phenylketonuria (PKU), a genetic disease that means her body can,t ... described by scientists as an autosomal recessive genetic disease that ...
Other Biology News:A world-first in solar technology unveiled at Concordia University 2New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease 2New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease 3
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... contains greater than 1500 known aptamer sequences. ...
... aptamer screening and binding optimization and built ... on-chip synthesis platform. Thousands of customer specified ... LC Sciences can provide assistance with custom ... part of our comprehensive DNA/RNA Aptamer Microarray ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... C-terminal end of the mouse retinoic acid receptor beta (RAR*). The ... RAR*. The sequence of PEP-005 is (amino to carboxy terminus): C ... - S - V - E - N - S - G ... - L - Q (The N-terminal cysteine has been added to ...
Biology Products: